Published in J Pathol on January 01, 1994
Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest (1999) 6.13
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev (2008) 3.17
Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer (2002) 1.62
Distribution of cervical intraepithelial neoplasia: are hysterectomy specimens sampled appropriately? J Clin Pathol (1995) 1.37
Early p53 alterations in mouse skin carcinogenesis by UVB radiation: immunohistochemical detection of mutant p53 protein in clusters of preneoplastic epidermal cells. Proc Natl Acad Sci U S A (1996) 1.36
Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy. Ann Surg (1999) 1.08
The consequence of oncomorphic TP53 mutations in ovarian cancer. Int J Mol Sci (2013) 1.07
Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas. PLoS One (2013) 1.03
Autoantibodies to tumor-associated antigens in breast carcinoma. J Oncol (2010) 0.96
Correlation of p53 over-expression and alteration in p53 gene detected by polymerase chain reaction-single strand conformation polymorphism in adenocarcinoma of gastric cancer patients from India. World J Gastroenterol (2009) 0.95
Prognostic value of p53 and Ki67 expression in fiberoptic bronchial biopsies of patients with non small cell lung cancer. Multidiscip Respir Med (2012) 0.94
Expression of p53 and C-myc genes and its clinical relevance in the hepatocellular carcinomatous and pericarcinomatous tissues. World J Gastroenterol (2002) 0.93
Oncogenomic Approaches in Exploring Gain of Function of Mutant p53. Curr Genomics (2008) 0.92
Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer. Br J Cancer (2007) 0.91
p53 abnormalities are rare events in neuroendocrine (Merkel cell) carcinoma of the skin. An immunohistochemical and SSCP analysis. Virchows Arch (1997) 0.91
AG490 influences UCN-01-induced cytotoxicity in glioma cells in a p53-dependent fashion, correlating with effects on BAX cleavage and BAD phosphorylation. Cancer Lett (2007) 0.89
Osteosarcoma occurring in osteogenesis imperfecta. Virchows Arch (2004) 0.88
Is p53 gene mutation an indicatior of the biological behaviors of recurrence of hepatocellular carcinoma? World J Gastroenterol (2003) 0.87
Gastrointestinal lymphomas in a North American population: clinicopathologic features from one major Central-Midwestern United States tertiary care medical center. Diagn Pathol (2012) 0.87
Expression of apoptosis-related markers in malignant epithelial tumours of the lacrimal gland and their relation to clinical outcome. Br J Ophthalmol (2007) 0.87
Prognostic markers for colorectal cancer: expression of P53 and BCL2. World J Surg (1997) 0.87
Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma. J Oncol (2010) 0.84
p53 and MDM2 protein expression in actinic cheilitis. J Appl Oral Sci (2008) 0.83
cDNA sequencing improves the detection of P53 missense mutations in colorectal cancer. BMC Cancer (2009) 0.83
p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab. Oncotarget (2014) 0.82
Expression of p53 predicts risk of prevalent and incident advanced neoplasia in patients with Barrett's esophagus and epithelial changes indefinite for dysplasia. Gastroenterol Rep (Oxf) (2015) 0.82
Discrimination of p53 immunohistochemistry-positive tumors by its staining pattern in gastric cancer. Cancer Med (2014) 0.81
P53 Overexpression as an Indicator of Overall Survival and Response to Treatment in Osteosarcomas. Pathol Oncol Res (1997) 0.80
p53 gene mutations in soft-tissue sarcomas--correlations with p53 immunohistochemistry and DNA ploidy. J Cancer Res Clin Oncol (1997) 0.80
Mutant p53 accumulates in cycling and proliferating cells in the normal tissues of p53 R172H mutant mice. Oncotarget (2015) 0.80
Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: a multivariate analysis of five antibodies. J Cancer Res Clin Oncol (1997) 0.80
Autoantibodies as biomarkers for ovarian cancer. Cancer Biomark (2011) 0.79
Assessment of p53 overexpression by non-immunohistochemical methods. J Pathol (1995) 0.79
Tumor-specific signaling to p53 is mimicked by Mdm2 inactivation in zebrafish: insights from mdm2 and mdm4 mutant zebrafish. Oncogene (2015) 0.78
SV40 Tag DNA sequences, present in a small proportion of human hepatocellular carcinomas, are associated with reduced survival. J Clin Pathol (2003) 0.77
Reduced P53 Staining in Actinic Keratosis is Associated with Squamous Cell Carcinoma: A Preliminary Study. Indian J Dermatol (2013) 0.77
Expression of the cell cycle regulation proteins p53 and p21WAF1 in different types of non-dysplastic leukoplakias. J Appl Oral Sci (2012) 0.76
The effect of red-allotrope selenium nanoparticles on head and neck squamous cell viability and growth. Int J Nanomedicine (2016) 0.76
Immunohistochemical study of p53 and proliferating cell nuclear antigen expression in odontogenic keratocyst and periapical cyst. J Pharm Bioallied Sci (2014) 0.75
Specific-mutational patterns of p53 gene in bladder transitional cell carcinoma among a group of Iraqi patients exposed to war environmental hazards. BMC Res Notes (2012) 0.75
The Janus face of p21. Mol Cell Oncol (2016) 0.75
Expression of p53 protein in rheumatoid arthritis synovium. An immunohistochemical analysis. Korean J Intern Med (1999) 0.75
Immunohistochemistry and scoring of Ki-67 proliferative index and p53 expression in gastric B cell lymphoma from Northern African population: a pilot study. J Gastrointest Oncol (2016) 0.75
Argyrophilic nuclear organizer region and p73 expression in head and neck squamous cell carcinomas: Teammates or adversaries? J Oral Maxillofac Pathol (2016) 0.75
Renal Cell Carcinomas in Vinylidene Chloride-exposed Male B6C3F1 Mice Are Characterized by Oxidative Stress and TP53 Pathway Dysregulation. Toxicol Pathol (2015) 0.75
Immunohistochemical expression of p53 and its clinicopathological correlation with modified Anneroth's histological grading system. J Oral Maxillofac Pathol (2016) 0.75
Recurrence of malignant tumours in the head and neck. BMJ (1996) 0.75
[Immunohistochemical expression of p53 protein in squamous epithelial carcinomas and normal and dysplastic epithelium of the mouth cavity]. Mund Kiefer Gesichtschir (1997) 0.75
The presence of aberrant p53 pattern is a negative prognostic predictor in squamous cell carcinoma of the nasal vestibule. Eur Arch Otorhinolaryngol (2017) 0.75
T antigen is bound to a host protein in SV40-transformed cells. Nature (1979) 17.78
Cancer. p53, guardian of the genome. Nature (1992) 16.36
The p53 pathway. J Pathol (1999) 6.79
Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J (1990) 6.34
Regulation of the specific DNA binding function of p53. Cell (1992) 6.16
Negative regulation of viral enhancers in undifferentiated embryonic stem cells. Cell (1985) 5.88
p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A (1990) 5.43
An immunoaffinity purification procedure for SV40 large T antigen. Virology (1985) 4.81
Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell (1993) 4.62
SUMO-1 modification activates the transcriptional response of p53. EMBO J (1999) 4.19
Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene (1990) 3.89
Monoclonal antibody analysis of p53 expression in normal and transformed cells. J Virol (1986) 3.72
p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ (2006) 3.49
SV40 large T shares an antigenic determinant with a cellular protein of molecular weight 68,000. Nature (1980) 3.44
Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci (1990) 3.35
p53 and DNA polymerase alpha compete for binding to SV40 T antigen. Nature (1987) 3.34
The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res (1994) 3.28
An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods (1992) 3.23
High levels of p53 protein in UV-irradiated normal human skin. Oncogene (1993) 3.15
Using the polymerase chain reaction to modify expression plasmids for epitope mapping. Nucleic Acids Res (1989) 3.15
Two pathways for base excision repair in mammalian cells. J Biol Chem (1996) 3.01
Small peptides activate the latent sequence-specific DNA binding function of p53. Cell (1995) 2.96
Thermodynamic stability of wild-type and mutant p53 core domain. Proc Natl Acad Sci U S A (1997) 2.90
Requirement for the replication protein SSB in human DNA excision repair. Nature (1991) 2.80
Nuclear protein with sequence homology to translation initiation factor eIF-4A. Nature (1988) 2.77
Use of monoclonal antibodies as probes of simian virus 40 T antigen ATPase activity. J Biol Chem (1981) 2.77
Localization of p53, retinoblastoma and host replication proteins at sites of viral replication in herpes-infected cells. Nature (1991) 2.75
Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol (2000) 2.72
A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J Pathol (1991) 2.71
Lassa fever in the United States. Investigation of a case and new guidelines for management. N Engl J Med (1990) 2.57
A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen. Curr Biol (1995) 2.57
Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer (1991) 2.52
Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1. Histopathology (1993) 2.52
An immunochemical investigation of SV40 T antigens. 1. Production properties and specificity of rabbit antibody to purified simian virus 40 large-T antigen. Virology (1978) 2.49
Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene (1991) 2.42
Structure and function of SV40 large-T antigen. Philos Trans R Soc Lond B Biol Sci (1987) 2.37
An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene (2000) 2.36
The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S+G2+M phase fraction (flow cytometric analysis) and prognosis. Histopathology (1991) 2.32
p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene (1997) 2.31
Epidermal growth factor (EGF/URO) induces expression of regulatory peptides in damaged human gastrointestinal tissues. J Pathol (1990) 2.29
Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. Proc Natl Acad Sci U S A (1998) 2.28
Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep (2001) 2.27
Allosteric activation of latent p53 tetramers. Curr Biol (1994) 2.25
Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol (1997) 2.25
Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. Oncogene (2001) 2.14
In situ end-labelling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol (1993) 2.07
DbpA: a DEAD box protein specifically activated by 23s rRNA. EMBO J (1993) 2.04
Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport. Nature (1991) 1.99
Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene (1999) 1.98
Nuclear protein p68 is an RNA-dependent ATPase. EMBO J (1989) 1.98
p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet (1991) 1.95
Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene (1994) 1.94
A role for the human single-stranded DNA binding protein HSSB/RPA in an early stage of nucleotide excision repair. Nucleic Acids Res (1992) 1.91
The prohibitin family of mitochondrial proteins regulate replicative lifespan. Curr Biol (1997) 1.86
P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer (2005) 1.83
High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci U S A (1997) 1.81
Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. J Pathol (1987) 1.80
Characterization of human p53 antigens employing primate specific monoclonal antibodies. Virology (1983) 1.78
Origins of the prestalk-prespore pattern in Dictyostelium development. Cell (1989) 1.78
Primary malignant lymphoma of the colon and rectum. A histopathological and immunohistochemical analysis of 45 cases with clinicopathological correlations. Histopathology (1988) 1.76
Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Bioessays (1995) 1.75
Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. J Mol Biol (1995) 1.75
An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs. Exp Cell Res (1999) 1.74
Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. Exp Cell Res (2001) 1.73
Do we really need a higher necropsy rate? Lancet (1999) 1.71
Cancer. A death in the life of p53. Nature (1993) 1.70
The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays (1993) 1.70
p68 RNA helicase: identification of a nucleolar form and cloning of related genes containing a conserved intron in yeasts. Mol Cell Biol (1991) 1.69
Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int J Cancer (1990) 1.69
Isolation and analysis of the fission yeast gene encoding polymerase delta accessory protein PCNA. EMBO J (1992) 1.68
Molecular characterization of the hdm2-p53 interaction. J Mol Biol (1997) 1.64
Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene (2012) 1.62
Gadd45 is a nuclear cell cycle regulated protein which interacts with p21Cip1. Oncogene (1995) 1.62
Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library. J Mol Biol (1992) 1.62
Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol (1991) 1.58
Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J Cell Sci (1995) 1.57
Mammalian prohibitin proteins respond to mitochondrial stress and decrease during cellular senescence. Exp Cell Res (2001) 1.57
The complexities of proliferating cell nuclear antigen. Histopathology (1992) 1.57
Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet (1992) 1.53
Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci U S A (2000) 1.52
Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. Oncogene (1995) 1.51
Endocrine cells of the human gastrointestinal tract have no proliferative capacity. Histochem J (1995) 1.49
Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res (1993) 1.49
The epidermal growth factor receptor in human pancreatic cancer. J Pathol (1992) 1.47
Ku selectively transfers between DNA molecules with homologous ends. J Biol Chem (1997) 1.46
Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. J Clin Pathol (1991) 1.46
Koch's postulates revisited. J Pathol (1991) 1.46
The p53 response to ionising radiation in adult and developing murine tissues. Oncogene (1996) 1.46
Ki67--structure, function, and new antibodies. J Pathol (1992) 1.45
APC expression in normal human tissues. J Pathol (1997) 1.44
Comparison of manual data coding errors in two hospitals. J Clin Pathol (1986) 1.42
Sensitive enzyme-linked immunosorbent assay for detection of Clostridium botulinum neurotoxins A, B, and E using signal amplification via enzyme-linked coagulation assay. J Clin Microbiol (1993) 1.41